Man Group plc Man Group Plc : Form 8.3 - Strongbridge Biopharma Plc
15 Septiembre 2021 - 5:14AM
UK Regulatory
TIDMEMG TIDM0A8E
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing Man Group PLC/Jersey
(Note 1)
-------------------------- ----------------------
Company dealt in STRONGBRIDGE BIOPHARMA
PLC
-------------------------- ----------------------
Class of relevant security $0.01 ordinary shares
to which the dealings
being disclosed relate
(Note 2)
-------------------------- ----------------------
Date of dealing 2021-09-14
-------------------------- ----------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long Short
--------------------------- -------------------------------- ---------------
Number (%) Number (%)
--------------------------- ------------------ ------------ -------- ----
(1) Relevant securities 1,966,636.00 2.8994 0.00 0.00
--------------------------- ------------------ ------------ -------- -----
(2) Derivatives (other
than options) 0.00 0.00 0.00 0.00
--------------------------- ------------------ ------------ -------- -----
(3) Options and agreements
to purchase/sell 0.00 0.00 0.00 0.00
--------------------------- ------------------ ------------ -------- -----
Total 1,966,636.00 2.8994 0.00 0.00
--------------------------- ------------------ ------------ -------- -----
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
--------------------------- -------------- ---------------
Number (%) Number (%)
--------------------------- ------- --- -------- ---
(1) Relevant securities
--------------------------- -------------- ---------------
(2) Derivatives (other
than options)
--------------------------- -------------- ---------------
(3) Options and agreements
to purchase/sell
--------------------------- -------------- ---------------
Total
--------------------------- -------------- ---------------
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Price per unit
Purchase/sale Number of relevant securities (Note 5)
--------------- ------------------------------ ---------------
Purchase 1,162 2.22
--------------- ------------------------------ ---------------
Purchase 120,415 2.22
--------------- ------------------------------ ---------------
Purchase 927 2.22
--------------- ------------------------------ ---------------
(b) Derivatives transactions (other than options transactions)
Product Nature of transaction Number of relevant Price per
name, (Note 6) securities unit
e.g. CFD (Note 7) (Note 5)
--------- --------------------- ------------------ ---------
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
---------- ------------ -------------- -------- --------------- ------ --------------------
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
----------------- -------------------------- -------------------
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
--------------------- ------------- --------------------
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any relevant securities to which any
derivative referred to on this form is referenced. If none, this
should be stated.
Is a Supplemental Form 8 attached? (Note 9) YES/NO
Date of disclosure 2021-09-15
---------------------------- -------------
Contact name Abdi Musse
---------------------------- -------------
Telephone number +442071443164
---------------------------- -------------
If a connected EFM, name
of offeree/offeror with
which connected
---------------------------- -------------
If a connected EFM, state
nature of connection (Note
10)
---------------------------- -------------
(END) Dow Jones Newswires
September 15, 2021 06:14 ET (10:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De May 2023 a May 2024